In a recent study on the market outlook for commercial bioprocessing, nearly half of respondents currently have marketed biologics to treat autoimmune disorders (47%) and cancer and related conditions (46%). Five years from now, two-thirds of respondents anticipate having marketed biologics that treat cancers and related conditions, making it the fastest growing indication slightly ahead of metabolic disorders. The therapeutic categories below represent the greatest anticipated growth (+10 percentage points or more) in biologics over the next five years.
View Resource